DOCTOR U

About DOCTOR U

DOCTOR U, operated by Wenyifuxin (Beijing) Medical Technology Co., Ltd., is a medical technology company specializing in artificial intelligence-assisted digital pathology. Founded in 2018, the firm develops solutions that aid pathologists in diagnosing cancer more efficiently and accurately. The company was co-founded by CEO Xiaoman Wang, who holds a Ph.D. in biomedical engineering from Tsinghua University and has a background as a former vice president at the medical AI company Deepwise.

The company's core offering is a digital pathology analysis system that leverages AI algorithms to analyze pathological slices. This system is designed to identify and analyze cancer cells, providing quantitative diagnostic information to assist doctors in making more precise diagnoses. Its product portfolio includes analysis software for various types of cancer, such as breast, lung, and cervical cancer, and it has obtained NMPA Class III medical device registration certificates for several of its products, including its AI-aided cervical cancer screening software. DOCTOR U's business model involves providing these AI-powered software solutions to hospitals and third-party medical laboratories. The technology addresses the shortage of experienced pathologists, particularly in primary care institutions, by automating parts of the diagnostic workflow and improving the consistency of diagnoses.